 |
Prospector
Profile
2-22-007
|
| |
| Oculus Innovative Sciences, Inc. |
NAICS |
541710 |
| 1129 N. McDowell Blvd.
Petaluma, CA 94954 |
Description |
Biotechnology |
| (707) 782-0792 |
Employees |
69 |
| http://www.oculusis.com |
Revenue |
(mil) |
3.6800 |
| |
Income |
(mil) |
-19.7800 |
| |
Assets |
(mil) |
26.9500 |
| |
Liability |
(mil) |
12.0500 |
| |
(for the year ended 2007-03-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Oculus Innovative Sciences, Inc., reported a net loss of $5.30 million on total revenues of $1.06 million for the third quarter ended December 31, 2007, slightly higher than the $4.82 million net loss on total revenues of $1.05 million reported during the third quarter of 2006. For the nine months ended December 31, 2006, the Company had a $15.86 million net loss on total revenues of $2.91 million, slightly higher than the $13.49 million net loss on total revenues of $3.38 million reported during the same period in 2006. As a result of its recurring losses, the Company has an accumulated deficit of $86.35 million at December 31, 2007.
|
| |
|
Intellectual Property:
The Company's portfolio of issued and pending applications is divided into two groups. The first group includes one U.S. issued patent, two issued European patents, three pending U.S. patent applications and five foreign patent applications that relate to early generation super-oxidized water product, methods of using super-oxidized water, and aspects of the method and apparatus for manufacturing super-oxidized water. The second group includes 10 pending U.S. patent applications and 15 foreign patent applications that relate to Microcyn, the method and apparatus for manufacturing Microcyn, and its uses. The Company has also filed for trademark protection for marks used with its Microcyn products in each of the United States, Europe, Canada, certain countries in Central and South America, including Mexico and Brazil, and certain countries in Asia, including Japan, China, the Republic of Korea, India and Australia. [SEC Filing 10-KSB 6-20-07]
|
| |
|
Description:
Oculus Innovative Sciences, Inc., together with its subsidiaries, operates as a biopharmaceutical company that develops, manufactures, and markets products based on the Microcyn Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds.
|
| |
|
Officers:
Hojabr Alimi (Chair, Pres. & CEO); Michael Wokasch (COO); Robert Miller (CFO); Bruce Thornton (VP - International Operations and Sales); James Schutz (VP - Corporate Development, Sec., General Counsel & Dir.)
|
| |
|
Auditor:
Marcum & Kliegman LLP
|
| |
|
Securities:
Common Stock Symbol OCLS; NasdaqGM; 13,271,035 common shares outstanding as of February 7, 2008.
|
| |
| |
| |
| return to main page |
|
|
